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’ INTRODUCTION
Advances in molecular biology and protein expression have
expanded the use of protein therapeutics in the pharmaceutical
industry, as well as provided numerous opportunities for the use of
engineered polypeptides for a range of materials science applica-
tions. Protein therapeutics often exhibit unique, highly specific
actions and fewer side effects compared to their small molecular
weight counterparts, particularly for treatment of metabolic and
immunological disorders.14 However, a ubiquitous challenge to
practical use of foldable proteins and polypeptides is preserving
their functions by avoiding irreversible conformational changes
during their production, processing, storage, and ultimate
application.512 Proteins ideally have the most stable conforma-
tions in their native or folded state due to the balance between
configurational entropy, solvation free energy, and energetic con-
tributions such as hydrogen bonding, van derWaals attractions, and
repulsive or attractive electrostatic interactions.6,11,13 In practice,
aggregates composed of unfolded or misfolded proteins and
polypeptides are often thermodynamically favored at finite protein
concentrations; however, their formation is kinetically limited due
to a need to significantly populate partially or fully unfolded
monomeric intermediates.14 Exposure of proteins to harsh chemi-
cal environments or to elevated temperature, pressure, or protein
concentrations, as well as the creation of mutations, can trigger the
formation of such aggregation-prone intermediate species, as
observed both in vitro and in vivo.1417 Given sufficient time,
aggregates often form even under mild storage conditions.18
Thus, stabilization of the native state and destabilization of the
interactions between the partially unfolded intermediates are usual
options to reduce protein aggregation.19 Multiple approaches, in-
cluding post-translational modifications such as glycosylation,20,21
as well as the use of chaperones,2224 stabilizing agents,2530 and
stabilizing fusions,3134 have been proposed to reduce protein
aggregation.
In many cases, irreversible aggregates are stabilized by
interprotein β-sheets,8,18 including proteins that are devoid
of β-sheet structures, such as helical proteins, in their native
state.7,35 In addition to their use here as models for helical
proteins, helical polypeptides also are of interest for use as
scaffolds to present ligands with desired spatial arrangements
for biotechnology and materials applications.3641 Funda-
mentally, the observation that proteins without native β-sheet
propensity form non-native, β-sheet rich aggregates raises
questions of how primarily helical polypeptides “find” their
way to β-sheet aggregates, as well as how to design them to
resist aggregation without jeopardizing the helical fold.
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ABSTRACT: The conformational and aggregation behavior of
PEG conjugates of an alanine-rich polypeptide (PEG-c17H6)
were investigated and compared to that of the polypeptide
equipped with a deca-histidine tag (17H6). These polypeptides
serve as simple and stimuli-responsive models for the aggrega-
tion behavior of helix-rich proteins, as our previous studies have
shown that the helical 17H6 self-associates at acidic pH and
converts to β-sheet structures at elevated temperature under
acidic conditions. In the work here, we show that PEG-c17H6
also adopts a helical structure at ambient/subambient tempera-
tures, at both neutral and acidic pH. The thermal denaturation
behavior of 17H6 and PEG-c17H6 is similar at neutral pH,
where the alanine-rich domain has no self-association tendency. At acidic pH and elevated temperature, however, PEGylation slows
β-sheet formation of c17H6, and reduces the apparent cooperativity of thermally induced unfolding. Transmission electron
microscopy of PEG-c17H6 conjugates incubated at elevated temperatures showed fibrils with widths of ∼2030 nm, wider than
those observed for fibrils of 17H6. These results suggest that PEGylation reduces β-sheet aggregation in these polypeptides by
interfering, only after unfolding of the native helical structure, with interprotein conformational changes needed to form β-sheet
aggregates.
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We have previously synthesized multiple families of recombi-
nant, glutamic acid-containing, alanine-rich helical polypeptides
as scaffolds to study multivalent interactions.3641 Given the
potential role of these alanine-rich sequences as simpler models
of aggregation-prone proteins, we have previously studied in
detail the association behavior of one of these polypeptides
(17H6, with the sequence given in Table 1). We have shown
in these previous studies that the polypeptide exhibits polymor-
phological behavior and self-associates to form folded, afibrillar
aggregates with an average hydrodynamic radius of∼1020 nm
at acidic pH, ambient temperature, and isotonic conditions.
Furthermore, 17H6 forms β-sheet fibrillar aggregates upon an
increase in temperature under those solution conditions;42
qualitatively similar fibril-formation behavior has been observed
in disease-related and therapeutic proteins such as R-synuclein16
and insulin.43 Detailed characterization of the self-assembly of
the fibrils indicated that they have an average width of∼78 nm
and likely a cross-β structure; a particularly useful feature of the
assembly is the periodic presentation of positively charged
patches along the fibril at subambient pH (owing to the
N-terminal histidine fusion tag), which has in turn permitted
the assembly of 1D nanoparticle arrays.44
Interestingly, cleavage of the deca-histidine tag (by cyanogen
bromide (CNBr) treatment) renders the polypeptide insoluble
at pH conditions below the pKa for Glu, suggesting the role of the
deca-histidine tag as a solubilizing agent. Recent studies have
shown that disordered flanks in some proteins,45 the acidic tail in
R-synuclein (ATS) derived peptides,3133 and late embryogen-
esis abundant (LEA) protein fusion34 can prevent aggregation of
peptides and proteins. Similarly, conjugation of poly(ethylene
glycol) to proteins has been shown to increase solution stability
of hydrophobic proteins4648 and improve thermal stability of
enzymes.4956 Moreover, superior to the fusion tags of biological
origin, PEG conjugation has also been demonstrated to increase
serum half-life and reduce immunogenicity of administered
proteins.5759 PEGylation, on the other hand, may result in
considerable loss of function if it disrupts the protein fold or
hinders the active site. The reduction of HER-2 binding affinity
of monoPEGylated scFv has been reported and attributed to
both intramolecular and intermolecular blocking by PEG chains
(20 kDa).60 Similarly, steric exclusion by PEG molecules of an
antigenantibody interaction has been demonstrated with in-
creasing PEG chain length (>10 kDa).61 In the case of PEG
polyalanine conjugates (with polyalanine molecular weight
∼ 0.7 kDa), self-assembled fibrillar nanostructures with β-sheet
conformation have been observed to switch to R-helical micellar
structures with increasing PEG chain length from 1 to 5 kDa.62
Conformational changes have also been reported for the other
PEG containing amphiphilic63 or coiled coil64,65 peptide hybrid
systems due to the steric interference of PEG chains. Thus, it is
possible that steric interference by PEG molecules could disrupt
the ability of a polypeptide such as 17H6 to reversibly associate,
which could disrupt fibril formation. It is also possible that PEG
attachment could destabilize the native structure of the polypep-
tide, triggering non-native aggregation, given that the folding free
energy of these polypeptides is not as high, nor the folding as
cooperative, compared to larger proteins. Despite these possibi-
lities, relatively few systematic, mechanistic studies focused
on the impact of PEGylation on the self-association, unfold-
ing, and aggregation behavior of proteins have been reported.6669
Given the polyconformational and polymorphological beha-
vior of 17H6, in this study we evaluated the effect of PEGylation
on the conformational, aggregation, and fibril formation behavior
of this aggregation-prone helical alanine-rich domain, as a model
system for the aggregation behavior of helix-rich proteins. The
deca-histidine tag was removed and the cleaved polypeptide
(alanine-rich domain) was modified with PEGs of two different
molecular masses (5 and 10 kDa with respective Rg values
70 of
∼2.1 and∼3 nmwhen untethered). The conformational stability
of the conjugates was probed via circular dichroic spectroscopy,
and their thermal transitions were monitored via differential
scanning calorimetry. Their tendency toward fiber formation
was characterized via transmission electron microscopy. While
PEGylation does not abolish the folded self-association of the
helical domain of the polypeptide, our data suggest it does
improve resistance of the polypeptide toward subsequent, non-
native β-sheet and fibril formation.
’MATERIALS AND METHODS
Materials. The monodisperse polypeptide, 17H6 (Table 1), was
expressed using an E. coli expression host, BL21(DE3)pLysS, and
purified using nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatog-
raphy by employing pH and imidazole gradients, as given elsewhere.38,39
Propionaldehyde-functionalized mPEGs (polydispersity indices < 1.05)
with molecular weights of 5 and 10 kDa were purchased from JenKem
Technology USA Inc. (Allen, TX) and Nanocs Inc. (New York, NY),
respectively. Reagent grade cyanogen bromide (CNBr) and sodium
cyanoborohydride (NaBH3CN) were obtained from Sigma-Aldrich.
Citrate buffer (50 mM) at pH 6.0 was prepared using sodium citrate
(Sigma) and citric acid (Sigma). Phosphate buffers at pH 2.3 were
prepared using 10 mM o-phosphoric acid (Fisher) and salt (140 mM
sodium chloride (NaCl; Fisher) and 10 mM potassium chloride (KCl;
Fisher)). Phosphate buffered saline (PBS) at pH 7.4 was purchased from
Thermo Scientific Inc. (Rockford, IL).
Synthesis of theConjugates.Thehistidine tag of 17H6was cleaved
via the cyanogen bromide (CNBr) reaction. A total of 100mg (∼6.8μmol)
polypeptide was dissolved in 20 mL of ∼62% (∼16.1 M) formic acid or
∼70% (∼9.1M) trifluoroacetic acid, and 500 mg (∼4.7 mmol) CNBr was
added and allowed to react at room temperature for∼1.5 days. CNBr and
the cleaved histidine tag were removed using a concentrator (Pierce
MWCO 9000) or a dialysis tube (ThermoFisher Snake Skin MWCO
10000) after diluting the reaction mixture with deionized water. The
dialyzed/concentrated solution was freeze-dried to yield the cleaved
Table 1. Amino Acid Sequences and Molecular Masses of the Polypeptides and the Conjugates
symbol amino acid sequence Mtheo (kDa) Mexp
a (kDa)
17H6 MGH10SSGHIHM(AAAQEAAAAQAAAQAEAAQAAQ)6AGGYGGMG 14.8 14.8
c17H6 (AAAQEAAAAQAAAQAEAAQAAQ)6AGGYGGS/S-lactone 12.4 12.3
PEG5K-c17H6 (mPEG5K)-(AAAQEAAAAQAAAQAEAAQAAQ)6AGGYGGS/S-lactone 17.4 17.5
PEG10K-c17H6 (mPEG10K)-(AAAQEAAAAQAAAQAEAAQAAQ)6AGGYGGS/S-lactone 22.4 22.0
a Peak maximum value in MALDI-TOF spectroscopy.
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polypeptide, c17H6 (Table 1). The yield of the purified c17H6 was
obtained to be ∼70 ( 10%, depending on the purification protocol.
Propionaldehyde-functionalized PEG (5 kDa or 10 kDa) was con-
jugated to the N-terminus of c17H6 via Schiff base formation and
subsequent reduction (Figure S1 in the Supporting Information). A total
of 150 mg (∼30 μmol) mPEG5K-propionaldehyde or 300 mg
(∼30 μmol) mPEG10K-propionaldehyde was added to a solution of
50 mg (∼4 μmol) of c17H6 (in 12.5 mL of citrate buffer containing
20 mMNaBH3CN at pH 6.0). The reaction mixture was stirred at room
temperature for ∼1 day. Unreacted PEG was removed via anion
exchange chromatography with a HiTrap diethylaminoethane (DEAE)
sepharose fast flow column (GE Healthcare Inc., Piscataway, NJ). The
20mMTris at pH 8.0 and 20mMTris and 1NNaCl at pH 8.0 were used
as starting and elution buffers, respectively, for the DEAE column
separations. MonoPEGylated conjugates, denoted as PEG5K-c17H6
and PEG10K-c17H6 (Table 1), were obtained using size exclusion
chromatography with a HiPrep 16/60 Sephacryl S-100 HR model size
exclusion column (GE Healthcare Inc., Piscataway, NJ). The 50 mM
sodium phosphate and 150 mM NaCl buffer at pH 7.2 were used as the
mobile phase in SEC separations. Both anion exchange and size
exclusion chromatography separations were performed on a fast protein
liquid chromatography (FPLC) system (AKTA Explorer 10 FPLC,
Amersham, Piscataway, NJ). The fractions obtained in SEC separations
were dialyzed against deionized water and the conjugate solutions in
deionized water were freeze-dried. The yield of the conjugates was
obtained to be ∼45 ( 10%. The production of monoPEGylated
conjugates was confirmed by gel permeation chromatography (GPC;
Figure S2) andmatrix-assisted laser desorption/ionization-time-of-flight
(MALDI-TOF) mass spectroscopy (Table 1). Sequences and molar
masses of the polypeptides and the conjugates (PEG5K- and PEG10K-
17H6, indicating the molecular weight of the PEG) are given in Table 1.
Characterization Methods. Circular dichroism (CD) experi-
ments were conducted using a Jasco (Easton, MD) J-810 spectro-
polarimeter with a Jasco PTC-424S Peltier temperature controller.
Temperature-induced spectral changes were monitored from 5 to
80 C in increments of 5 C with a temperature increment rate of
1 C/min. Prior to refolding experiments, each sample was further
incubated at 80 C for 3 h. Refolding spectra were collected during
cooling from 80 to 5 C with the same increments as unfolding
experiments and 1 C/min cooling rate. CD kinetic experiments were
performed at 80 C for 18 h followed by the refolding experiments as
desribed above. All the spectra were taken between 250 and 190 nm at a
rate of 50 nm/min and were corrected by subtraction of the correspond-
ing buffer spectrum. Mean residue ellipticity values, [Θ]MRE (deg cm
2
dmol1), were obtained using concentration, number of amino acids of
the polypeptide, and the cell path length.71 Helical content was
estimated by the equation given in Kennedy et al. (2002).72 Thermal
melting curves were constructed by recording ellipticity at 222 nm,Θ222,
every 1 C during steady heating at a rate of 1 C/min. Consecutive
melting curves were obtained using the same temperature range,
incubation time, heating, and cooling rate as those employed in diffe-
rential scanning calorimetry (DSC) experiments.
DSC experiments were carried out using a VP-DSC (Microcal, North-
hampton, MA). DSC curves were taken between 5 and 85 C at a heating
rate of 1 C/min. For the consecutiveDSCscans, the samplewas cooledback
to 5 C after reaching 85 C (without incubation at 85 C) with a cooling
rate of 1 C/min. Then, the sample was incubated at 5 C for 15 min and
heated again using the same parameters as those of the previous heating scan.
Transmission electron microscopy (TEM) of the samples was
performed using a Tecnai G2 12 TEM (FEI Company, Hillsboro,
OR) at an acceleration voltage of 120 keV. The samples were stained
using uranyl acetate as described in a protocol given elsewhere.42
’RESULTS AND DISCUSSION
Conformation and Thermal Denaturation Behavior at
Neutral pH. In the first part of this study, the effect of PEGyla-
tion on the conformational behavior of the alanine-rich poly-
peptide (c17H6, indicating cleavage of the deca-histidine tag
from the 17H6) was investigated for comparison to our previous
studies of the uncleaved polypeptide. The uncleaved 17H6 has an
R-helical conformation at low and ambient temperatures, in-
dependent of pH. It was also shown that the polypeptide forms
monomeric species at neutral pH, while it spontaneously forms
aggregates of folded monomers at acidic pH, triggered by the
protonation of glutamic acid residues. We also showed that 17H6
exhibited pH-dependent thermal denaturation behavior,42
suggesting the impact of intermolecular association on the
denaturation of the polypeptide. Therefore, we investigated
the conformational and thermal denaturation behavior of the
PEGylated samples both at neutral and acidic pH.
Temperature-induced conformational changes were moni-
tored using CD spectroscopy. The CD spectra of the cleaved
polypeptide and the conjugates at pH 7.4 are given in Figures S3,
S4, and S5 for c17H6, PEG5K-c17H6, and PEG10K-c17H6,
respectively. At low temperatures, the CD spectra of c17H6 and
both conjugates exhibited minima at 208 and 222 nm, character-
istic of the R-helical conformation; the spectra of the conjugates
were essentially identical to that of the parent molecule, 17H6.
The helicity values of c17H6 and the conjugates at 5 C,
estimated using mean residue ellipticity values at 222 nm,72 were
approximately 6265%. There were no significant differences in
the conformation and helicity of the parent polypeptide and the
conjugates at neutral pH and 5 C (Table 2). These observations
are consistent with previous studies describing nonspecific
PEG attachment to the surface amines of insulin,67 antibody
fragments,73 and human serum albumin,74 in which PEGylation has
Table 2. [Θ]MRE,222 and % Helicity Values before Unfolding and after Refolding
sample pH
unfolding
[Θ]MRE,222  103
(mdeg cm2 dmol1)
average
% helicity
prior to unfolding
refolding
[Θ]MRE,222  103
(mdeg cm2 dmol1)
average
% helicity
after refolding
17H6 7.4 36.0 ( 0.1 60 ( 1 37.2 ( 1.7 62 ( 3
c17H6 7.4 37.0 ( 0.5 62 ( 1 37.7 ( 0.5 63 ( 1
PEG5K-c17H6 7.4 39.0 ( 2.6 65 ( 4 39.7 ( 2.7 66 ( 5
PEG10K-c17H6 7.4 38.8 ( 0.3 65 ( 1 39.9 ( 0.2 67 ( 1
17H6 2.3 39.3 ( 0.7 65 ( 1 29.7 ( 0.3 50 ( 1
PEG5K-c17H6 2.3 39.1 ( 2.5 65 ( 4 38.7 ( 2.4 65 ( 4
PEG10K-c17H6 2.3 38.4 ( 2.5 64 ( 4 38.1 ( 2.5 64 ( 4
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been reported to have nomeasurable impact on the conformation of
the parent peptides/proteins. On the contrary, in some cases, PEG
conjugation is deleterious to the secondary structure as observed in
the conjugation of 5 kDaPEG tomultiple lysines in cytochrome c, as
suggested by changes in the CD spectrum of the protein. However,
the reduction of R-helical content in that case did not result in any
reported activity loss.53
To assess the relative stabilities of the polypeptide and its
modified forms, we carried out thermal denaturation experi-
ments using CD spectroscopy and DSC. As shown in the CD
spectra in Figures S3, S4 and S5, the polypeptide and the
conjugates all exhibited a temperature-induced transition be-
tween the R-helical and nonhelical conformation, with recovery
of the R-helical structure upon cooling. The essentially complete
recovery of the [Θ]MRE,222 by all of the samples upon cooling
indicates complete recovery of conformational changes at neutral
pH (Table 2). CDmelting curves (recorded at 222 nm) andDSC
thermograms of the polypeptides and the conjugates are given in
Figures S6 and S7, respectively. No significant changes in the
melting curves and in the apparent melting temperature (Tm)
were observed, with the peptide and both conjugates showing an
apparent melting temperature of 36( 1 C. Tm was taken as the
temperature at which the normalized ellipticity was 0.5. In the
DSC curves, all the samples presented a similarly broad en-
dotherm with a peak maximum of approximately 37 ( 1 C
without establishment of clear pre- or post-transition baselines;
the latter feature precludes determination of valid calorimetric or
van’t Hoff enthalpies from the DSC data and is not unexpected
for unfolding that is multistate, such as for isolated helices.75 The
reversibility of the transition was monitored by comparison of
consecutiveDSC scans (Figures S8S10).The cleaved polypeptide
and the conjugates showed a quantitatively reversible transition as
that observed for 17H6, corroborating the CD data. The similarities
of the peak maximum values in the DSC curves, the overlay of the
melting curves, and the reversibility of the transitions confirm that
N-terminal PEGylation had no discernible impact on the conforma-
tional behavior, at ambient pH, of the polypeptide domain.
Despite the lack of any conformational impact of PEGylation
in the case of 17H6, there are some reports indicating a modest
increase in the thermal stability of globular proteins such as
trypsin,49,52,56 laccase,54 and R-chymotrypsin55,69 upon modifi-
cations of the surface lysines with PEG groups. The increased
thermal stability observed in these previous studies was attrib-
uted to the reduced structural flexibility of the proteinPEG
conjugates, indicated by H/D exchange kinetic studies.55 There-
fore, in the relatively simple case of 17H6 and the conjugates, it is
likely that the N-terminal conjugation of PEG moieties, as
investigated in the current study, does not significantly affect
the structural flexibility of the polypeptide.
Conformational and Thermal Denaturation Behavior at
Acidic pH. Under acidic conditions, the potential role of the
positively charged histidine tag or of the PEG is to solubilize the
alanine-rich block, which has a tendency to associate via hydro-
phobic interactions owing to the protonation of glutamic acid
residues and the inherent hydrophobicity of Ala side chains.
Evaluation of the conformational and thermal denaturation
behavior of these macromolecules under acidic conditions may
thus give some information about the stability of the associated
hydrophobic domains when a relatively hydrophilic or nonasso-
ciating domain is attached. Temperature-induced conformational
changes of PEG5K-c17H6 and PEG10K-c17H6 in pH 2.3 buffer
were monitored via CD spectroscopy; results are presented in
Figure 1 and Figure S11, respectively. It was not possible to
acquire a spectrum for the c17H6 at pH 2.3, owing to its poor
solubility under these conditions. In contrast, the parent poly-
peptide and its conjugates were soluble at acidic pH, and an R-
helical conformation was conserved in all cases. Helicity values
were ∼65% for all samples (Table 2) and were similar to those
presented above for the samples at neutral pH, indicating that
there was no significant effect of either the pH shift or the
N-terminal tag on the conformation of the polypeptide at low
temperature. These results are consistent with those reported for a
self-associating coiled-coil peptide,76 and a silk-like polypeptide,77
and tetrapeptides78 inwhich no significant change in conformation
was observed upon PEGylation. On the contrary, introduction of
PEG chains has resulted in considerable or mild/moderate con-
formational changes for some amphiphilic62,63 or coiled coil64,65
peptides, respectively, suggesting that the impact of PEG chain on
the conformation of the self-associating peptide/polypeptide
domain is strongly dependent on the nature of the peptide/poly-
peptide block and PEG chain length.
However, a significant difference between the thermal dena-
turation behavior of 17H6 and the conjugates was revealed by
comparison of the extent of refolding after extended heating at
high temperatures. The differences in the [Θ]MRE,222 and %
helicity values prior to unfolding and after refolding are presented
in Table 2. Unlike the polypeptide equipped with the deca-
histidine tag, the PEGylated polypeptides showed essentially
complete refolding upon cooling after incubation at 80 C for 3 h,
with no significant loss compared to their initial R-helical
contents. To assess whether PEGylation thermodynamically
Figure 1. CD spectra of 50 μM PEG5K-c17H6 in pH 2.3 buffer during
(A) unfolding upon increasing temperature from 5 to 80 C and (B)
refolding upon decreasing temperature from 80 to 5 C subsequent to
the incubation at 80 C for 3 h.
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stabilizes native R-helical structures relative to unfolded mono-
mers, CD melting curves (Figure 2) were compared. Apparent
melting temperatures from the CD melting curves were estimated
as ∼54 C for 17H6 and PEG5K-c17H6 and ∼51 C for PEG-
10K-c17H6 at a concentration of 50 μM. These similar or even
reduced apparent melting temperatures of the conjugates, when
compared to 17H6, clearly indicate that the high temperature
stability of the conjugates is not due to conformational stabilization
of the native R-helical conformation upon PEGylation.
Although there is no significant difference in the apparent
melting temperatures of the polypeptide and the conjugates, the
shapes of the melting curves were observed to be quite different.
Initially, as shown in Figure 2, 17H6 unfolds to a lesser extent
with increasing temperature than do the conjugates, but then at
temperatures above ∼45 C, unfolds with a greater temperature
sensitivity (i.e., much more “cooperatively”) than do the con-
jugates. Together, this leads to net midpoint unfolding tempera-
tures that are similar between 17H6 and the conjugates. Given
the improved thermal stability of PEGylated enzymes on the
basis of hydrogen-bonding contacts in the conjugates,49,51 as well
as the decreased temperature sensitivity of the conformation of
amphipilic and coiled coil peptides upon PEGylation,63,64 it was
expected that the conjugates would be more resistant to unfold-
ing, as opposed to the experimental observations. However, as
previously shown, the native self-association of 17H6 at low pH
provides some of the conformational stability, with higher Tm
values for self-associated helix multimers than for the isolated
monomer.42 Small-angle neutron scattering experiments (SANS,
unpublished data) suggest that 17H6 has a higher aggregation
number than the conjugates; the greater number of molecules in
the aggregates would provide additional interactions within the
aggregate structure to resist unfolding. This presumably is simi-
lar in spirit to the behavior of multimeric proteins such as
β-glucosidase79 or transthyretin,80 in which native multimer
formation provides significant stabilization of the individual
folded chains. Thus, it is likely that the difference in the initial
aggregation state/compactness of the polypeptide and the con-
jugates has a significant effect on their relative unfolding free
energies.
Detailed analysis of the thermal transitions of 17H6 and the
conjugates, at acidic pH and concentrations of 100 μM (monomer
basis), was conducted via DSC (Figure 3). For 17H6 and the
conjugates, theDSC curves show onemajor endothermwith a low-
temperature shoulder and a high-temperature exotherm consistent
with irreversible aggregate formation, confirming that the thermal
transition has multiple components, in contrast to the neutral pH
case. One major difference in the DSC curves of 17H6 and the
conjugates is the relative magnitudes of the endotherms at∼60 C,
which may represent a difference in packing/aggregation of the
folded aggregate (i.e., low temperature state) and unfolding of the
helix, suggesting a correlation of the peak area with the aggregation
number determined by SANS. Any interpretation of slight differ-
ences in the position of exotherms is complicated by the difficulties
in the baseline determination, making conclusions about variations
in the onset of aggregation with PEGylation difficult. However, it is
clear from these DSC curves that PEGylation does not completely
prevent aggregation of the 17H6 at high temperatures. Previous
reports of PEG conjugation to aggregation-prone proteins have
yielded variable results with respect to aggregation. In most cases,
the aggregation propensity of the conjugates was observed to be
lowered compared to that of the parent proteins, at least putatively
due to steric hindrance by PEG molecules.6668,77 However, in a
specific case in which PEG is attached to a buried amino acid of
granulocyte colony stimulating factor (G-CSF), PEGylated G-CSF
exhibited faster aggregation compared to G-CSF, which is likely a
result of exposure of some hydrophobic residues.81 In the case of
17H6, N-terminal conjugation with PEG at least slowed the
conversion from helical aggregates to β-sheet aggregates (see also
the discussion of Figure 5 below).
Consecutive DSC scans of the conjugates under acidic condi-
tions were also taken to provide complementary information
about the reversibility of the transition obtained from CD data,
although at a higher concentration, owing to signal-to-noise
limitations in the DSC experiment (Figures 4 and S12). Con-
secutive DSC scans of 17H6 indicated a gradual decrease in the
peak intensity in subsequent heatingcooling cycles, suggesting
irreversible aggregation.42 However, those of the PEGylated
samples showed that after the drop of intensity observed between
the first and second scans, no changes in the following scans were
observed. To check whether the changes in the DSC data are
associated with conformational changes in the polypeptide, CD
melting experiments at 222 nm were performed under the same
conditions (concentrations of 100 μMand same heating/cooling
rates). Although it was not possible to collect a full-wavelength
spectrum at the higher concentrations, reliable ellipticity values at
222 nm were possible to obtain. The resulting melting curves are
presented in Figure S13, showing behavior that is semiquantita-
tively similar to that observed in the DSC experiments; 17H6 is
conformationally reversible in the first two heating/cooling
Figure 2. Comparison of CD melting curves of 17H6 (circles), PEG5K-
c17H6 (squares), and PEG10K-c17H6 (triangles) at pH2.3 (C= 50μM).
Figure 3. Comparison of the first DSC scans of 17H6 (solid line),
PEG5K-c17H6 (dashed line), and PEG10K-c17H6 (dotted line) in pH
2.3 buffer (C = 100 μM).
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cycles, but loses reversibility in the third and subsequent cycles
(Figure S13A), exhibiting β-sheet conformation at the end of the
fifth scan (data not shown). PEGylated samples, on the other
hand, experienced no loss of reversibility of the conformational
transition (Figure S13B,C) nor any measurable change in the
reliable portion of the spectra for these high peptide concentra-
tions (∼210250 nm) after heating/cooling cycles (i.e., no loss
of the helical conformation after refolding). These findings,
along with those below, suggest that some portion of the
aggregation is reversible in the case of the PEGylated conju-
gates and irreversible conformational changes are significantly
less than those observed for 17H6 upon thermal denaturation
and refolding.
β-Sheet Tendency and Fibril Formation Behavior at Acidic
pH. It was previously shown that 17H6 undergoes β-sheet
formation and fibrillization upon incubation at low pH and
80 C for prolonged time periods.42 Similar experiments were
carried out with PEGylated samples in order to assess the
tendency of the conjugates to form β-sheet structures relative
to the unmodified polypeptide. CD spectra for samples (50 μM)
in pH 2.3 buffer at 80 Cwere collected at various intervals over a
period of 18 h (Figure 5), and then full-wavelength spectra of the
samples during cooling were collected at various temperatures
from 80 to 5 C, as shown in Figure 6. The PEG5K-c17H6
conjugate ultimately adopted β-sheet structure (CDminimum at
ca. 218 nm) upon incubation at 80 C (Figure 5A), with only a
small fraction of the initial R-helical structure recovered upon
cooling (Figure 6A). PEG10K-c17H6, on the other hand,
showed mainly a signal at 205 nm, consistent with a nonhelical
structure (Figure 5B), with this signal only decreasing in intensity
over time. In the refolding experiments for PEG10K-c17H6
shown in Figure 6B, it is apparent that the PEG10K-c17H6
conjugate regains a greater amount of helicity than the PEG5K-
c17H6 and, although the high-temperature spectrum did not
show a significant contribution from β-sheet, that some fraction
of the original R-helical structure (∼30%) was lost for the PEG-
10K-c17H6 conjugate.
The rate at which the random-coil structure was transformed
to the β-sheet structure for 17H6 and the conjugates was
monitored by evaluating the change in [θ]MRE,205 as a function
of time (Figure 7). As shown in Figure 7, 17H6 showed a
sigmoidal time course for β-sheet formation whereas PEGylated
Figure 5. CD spectra, collected at 1 h intervals upon incubation at 80
C for 18 h, of 50μMsolutions of (A) PEG5K-c17H6 and (B) PEG10K-
c17H6 in pH 2.3 buffer.
Figure 4. Consecutive DSC scans of PEG5K-c17H6 in pH 2.3 buffer.
The first scan is given as a dotted line; the other scans are represented as
a solid line.
Figure 6. CD spectra obtained upon cooling of solutions of (A)
PEG5K-c17H6 and (B) PEG10K-c17H6 from 80 to 5 C, at 5 C
temperature intervals, subsequent to the incubation at 80 C for 18 h.
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samples showedmainly linear trends with a slowed rate of β-sheet
formation; this effect was more prominent for the 10K PEG. It is
apparent from these data that the conjugation of the PEG chain
reduces the rate of β-sheet formation of the polypeptide domain.
It seems plausible that this is due to predominantly steric
hindrance, perhaps via the relatively large PEG end groups
limiting the number of amino acids per 17H6 chain that can be
proximal to form hydrogen bonds within the β-sheets, although
variations in the hydrophobichydrophilic balance of these
conjugates may also play a role. A similar effect has been
previously observed for proteins modified with PEGs of similar
length as those employed here; specifically, longer PEG chains
(ca. 2000 or 5000 Da) have been reported to reduce the
aggregation rate more efficiently than shorter PEG chains
(ca. 750 or 1000 Da) for trypsin56 and insulin.66,67 These findings
support that the improvement in the apparent thermal stability of
the alanine-rich block imparted by the N-terminal PEG segments
(compared to stabilization imparted by the deca-histidine tag) is
likely due to the stabilization not of the native helical structure
(see above) but of the nonhelical intermediate structures that
form prior to β-sheet aggregation; the PEG likely reduces
intermolecular interactions between random coil or early stage
β-sheet structures but still allows native self-association when Glu
side chains are protonated and the molecule is folded.
Themorphologies of the species that form at high temperature
and prolonged incubation were characterized via TEM and are
shown in Figure 8 and 9 for PEG5K-c17H6 and PEG10K-c17H6,
respectively. The images were acquired after first cooling the
samples to room temperature, thus the images represent what
remained aggregated after cooling; the DSC data (Figure 4)
suggests that much of the sample remains aggregated after
cooling for the samples at low pH. Nonuniform and wider fibrils
(∼2030 nmwidth) were observed for both the PEG5K-c17H6
and PEG10K-c17H6 conjugates (Figure 8 and 9) compared to
the previously reported widths of the 17H6 fibrils (∼7.5 nm
width42,44), but there was no clear dependence of fibril width on
PEG chain length. In the case of PEG10K-c17H6, fibrils like those
in Figure 8 were present in small amounts, but the samples showed
primarily short fibrils and bead-like structures (Figure 9). Similarly,
shorter fibrils have been observed for other PEGylated, β-sheet-
forming polypeptides; in the case of the PEGpolypeptide
PEG conjugates (for silk-like polypeptides), shorter fibrils were
observed with increasing PEG molecular weight, indicating sig-
nificant interference of the longer PEG chains with the stacking of
the β-sheet structures.77 Pronounced morphogenic effects of the
PEG chain length (350, 1200, 1800 Da) have also been observed
for PEG-hydrophobic tetrapeptide (F4 or V4) conjugates. For
PEG-F4 conjugates,
78 nanotubes, fibrils, and worm-like micelles
have been obtained as the PEG chain increases in length, similar to
the behavior of PEG-polyalanine conjugates.62 On the other hand,
an increase in PEG chain length increases the population of
uniform structures (fibrils) over ill-defined aggregates (plank-like
structures) in the case of PEG-V4 hybrids. Hence, the differences in
the structures obtained from the self-assembly of PEG-F4 and
PEG-V4 conjugates have clearly indicated that the nature of the
peptide block is also important in the self-assembly process.78
Most previous studies on the morphogenic effect of PEG
conjugation, on the other hand, have focused on PEG-amyloid
peptide conjugates. The major reported impact of PEG on fibril
formation has been to inhibit the lateral fibril interactions.63,82
Previous SANS studies and negative-stained TEM images of
PEG-amyloid peptide conjugates have shown that PEG coats
the surface of the fibrils.8284 In cryo-TEM images of an amyloid
β-peptide fragment attached to different molecular weights of
PEG, no significant difference in the width of the fibrils was
observed, in agreement with the coreshell nature of the fibrils.85
In our study, we also observed the lack of impact of PEG chain
length on the stained portion of the fibrils, consistent with these
previous findings. However, the width of the fibrils formed by the
conjuguates is significantly greater than those of the 17H6
fibrils.42,44 The greater width of the PEGylated polypeptides is
not a result of visualization of the PEG fragments, as these
polymers are not stained by the negative staining method. In our
proposed model of the fibril self-assembly of 17H6, the∼7.5 nm
Figure 7. Comparison of the change in [θ]MRE,205 over time, with incu-
bation at 80 C, of 17H6 (circles),42 PEG5K-c17H6 (squares), and
PEG10K-c17H6 (triangles).
Figure 8. TEM images of PEG5K-c17H6 at pH 2.3, after incubation at
80 C for 18 h. Scale bars: (A) 500 nm, (B) 100 nm.
Figure 9. TEM images of PEG10K-c17H6 at pH 2.3, after incubation at
80 C for 18 h. Scale bars: (A) 200 nm, (B) 100 nm.
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fibril width is ascribed to an antiparallel, folded β-sheet
structure.44 Thus, it is possible that the conjugation of PEG
chains of even moderate molecular weight and size (Rg values of
∼23 nm) interferes with folding of the polypeptide chains
during or prior to the fibril formation, allowing longer sections of
the chain to adopt intra- (and/or inter-) molecular β-sheet
structures during fibrillization, which results in wider fibrils;
alternatively, the N-terminal regions of the PEGylated peptides
could simply be more difficult to pack tightly within the “spine”
of the fibrils and so could be forced to be more flexible and
expanded, thus, giving effectively wider fibrils due to the steric
constraints of packing the PEG chains along the corona or
periphery of the fibrils. More detailed investigations of the
fibrillization behavior of conjugates with various length PEGs
could provide insight into the contacts made between amino
acids during aggregation and fibril formation. Although determi-
nation of detailed reasons for the differences between the
morphology of the polypeptide 17H6 and its conjugates is
beyond the scope of this report, the results clearly show that
N-terminal PEGylation does not completely prevent the non-
native aggregation product, fibrils, but that, as PEG chain length
increases, fibril formation is impeded.
’CONCLUSIONS
In this study, the effect of PEG conjugation on the folded
conformation, thermal denaturation, and fibrillization behavior of
an alanine-rich helical polypeptidewas investigated. It was observed
that N-terminal PEGylation did not change the helicity of the
polypeptide at low temperature, independent of solution pH. The
thermal stability and denaturation behavior at neutral pH was also
unaffected. However, the impact of PEGylation was pronounced at
acidic conditions, under which the polypeptide has been demon-
strated to self-associate. PEGylation retarded β-sheet formation
and fibrillization, and this was attributed to net reduction of
attractive interactions between aggregation-prone intermediate
unfolded structures, as well as to steric interference with the chain
mis- or refolding that is necessary for conversion to β-sheet fibrils.
The conjugation of PEG of higher molecular weight more sig-
nificantly retarded formation of β-sheet fibrils, consistent with the
increased steric interference expected for the larger macromolecule
conjugate. It was also observed that PEGylation changed the fibril
morphology to some degree, possibly by interfering with the
folding of β-sheet structures in the alanine-rich domain. In conclu-
sion, N-terminal PEGylation did not significantly change the native
conformational behavior but improved resistance of the prefibril,
unfolded structures to formation of non-native, β-sheet interpro-
tein contacts. Our results suggest the utility for these PEGylated
polypeptides as useful model systems for the investigation of the
aggregation properties of helix-rich proteins with additional appli-
cation in the control of assembled nanostructures.
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